Brief: Krystal Bio Receives FDA Fast Track Designation For Inhaled Oncology Candidate KB707
13/02/2024 12:43
Feb 13 (Reuters) - Krystal Biotech Inc KRYS.O :
* KRYSTAL BIOTECH RECEIVES FDA FAST TRACK DESIGNATION FOR
INHALED
ONCOLOGY CANDIDATE KB707 TO TREAT SOLID TUMORS OF THE LUNG
* KRYSTAL BIOTECH INC: FDA CLEARS IND AND PHASE 1
(KYANITE-1)
CLINICAL TRIAL EXPECTED TO BE INITIATED IN 1H 2024
Source text for Eikon: ID:nGNX7RnNWx
Further company coverage: KRYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion